Valuation: Immatics N.V.

Market Cap 100Cr 89Cr 83Cr 75Cr 140.08Cr 9.51TCr 142.38Cr 994.74Cr 393.48Cr 4.97TCr 375.02Cr 367.01Cr 16TCr P/E 2026 *
-3.44x
P/E 2027 * -3.5x
Enterprise Value 72Cr 65Cr 60Cr 54Cr 101.31Cr 6.88TCr 102.97Cr 719.41Cr 284.57Cr 3.6TCr 271.22Cr 265.43Cr 11TCr EV / Sales 2026 *
15.9x
EV / Sales 2027 * 16.9x
Free-Float
76.83%
Yield 2026 *
-
Yield 2027 * -
1 day-2.19%
1 week+6.24%
Current month-18.56%
1 month-14.58%
3 months-21.26%
6 months-37.00%
Current year-31.90%
1 week 6.94
Extreme 6.935
7.95
1 month 6.65
Extreme 6.65
9.16
Current year 6.65
Extreme 6.65
11.94
1 year 6.65
Extreme 6.65
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
14.9
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26
Perceptive Advisors LLC
BuyCompany 8,63,060 0.6436%
18/03/26 Other

Chief Financial Officer

3,50,000 0.2611%
18/03/26 Other

Head of Human Resources

2,11,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-2.19%+6.24%-29.76%-12.27% 100Cr
+0.88%+1.18%+40.64%+74.91% 6.47TCr
-0.26%+7.23%+11.14%+74.78% 5.48TCr
+0.47%+5.10%+8.22%+101.52% 5.35TCr
-2.06%+2.51%+24.07%+50.98% 4.6TCr
-1.79%+0.49%+19.32%+122.77% 4.29TCr
-1.65%+3.34%+237.56%+819.04% 4.01TCr
-2.26%-2.06%+15.38%+45.14% 3.35TCr
+0.22%-4.77%+26.59%+0.55% 2.4TCr
+12.10%+18.47%+55.14%+45.58% 2.37TCr
Average +0.35%+2.86%+40.83%+132.30% 3.84TCr
Weighted average by Cap. +0.11%+2.60%+45.73%+149.45%

Financials

2026 *2027 *
Net sales 4.56Cr 4.08Cr 3.77Cr 3.41Cr 6.39Cr 433.61Cr 6.49Cr 45Cr 18Cr 226.8Cr 17Cr 17Cr 718.09Cr 3.95Cr 3.54Cr 3.27Cr 2.96Cr 5.54Cr 376.13Cr 5.63Cr 39Cr 16Cr 196.73Cr 15Cr 15Cr 622.9Cr
Net income -29Cr -26Cr -24Cr -21Cr -40Cr -2.72TCr -41Cr -284.14Cr -112.39Cr -1.42TCr -107.12Cr -104.83Cr -4.5TCr -31Cr -28Cr -26Cr -23Cr -44Cr -2.96TCr -44Cr -310.11Cr -122.67Cr -1.55TCr -116.91Cr -114.42Cr -4.91TCr
Net Debt -28Cr -25Cr -23Cr -21Cr -39Cr -2.63TCr -39Cr -275.33Cr -108.91Cr -1.38TCr -103.8Cr -101.58Cr -4.36TCr -33Cr -29Cr -27Cr -25Cr -46Cr -3.14TCr -47Cr -328.21Cr -129.83Cr -1.64TCr -123.74Cr -121.09Cr -5.19TCr
Projected Income Statement - Annual - Immatics N.V.
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
27/26/27 $7.150 -2.19% 7,56,091
23/26/23 $7.310 -3.05% 6,95,978
22/26/22 $7.540 -1.95% 6,21,016
21/26/21 $7.690 +2.40% 19,80,384
20/26/20 $7.510 +6.52% 14,87,260
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immatics N.V.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.310USD
Average target price
16.97USD
Spread / Average Target
+132.17%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immatics N.V.
  1. Stock Market
  2. Stocks
  3. IMTX Stock